Cardiovascular outcomes of antidiabetic drugs
نویسندگان
چکیده
منابع مشابه
Cardiovascular Safety of Oral Antidiabetic Drugs
SAŽETAK: Hrvatska pripada skupini europskih zemalja s visokim kardiovaskularnim rizikom i rastućom prevalencijom šećerne bolesti tipa 2 (DMT2). Prema podatcima Nacionalnog registra osoba sa šećernom bolešću (CroDiab registar), u Hrvatskoj je 2014. godine bilo evidentirano ukupno 254 296 osoba oboljelih od dijabetesa starijih od 18 godina (7,9 %). DMT2 je, uz hipertenziju i hiperlipidemiju, jeda...
متن کاملThiazolidinediones: antidiabetic drugs with cardiovascular effects.
cardiovascular morbidity and mortality at least four times higher compared to patients without diabetes. Moreover, it is well established nowadays that the cardiovascular risk of diabetic patients without a history of a prior myocardial infarction is similar to the risk of nondiabetic patients who have already had one. Hence, the reduction of cardiovascular risk in type 2 diabetic patients usin...
متن کاملCardiovascular safety outcomes of new antidiabetic therapies.
PURPOSE The cardiovascular safety outcomes of newer antidiabetic agents were reviewed. SUMMARY Seven randomized, placebo-controlled trials involving patients with type 2 diabetes mellitus with or at risk for cardiovascular disease were reviewed. The trials examined the cardiovascular safety outcomes of the following agents: alogliptin, saxagliptin, and sitagliptin (dipeptidyl peptidase-4 [DPP...
متن کاملCardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
OBJECTIVE To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice. DESIGN Population based retrospective cohort study. SETTING Nationwide sample of patients with type 2...
متن کاملRecent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
Since the rosiglitazone controversy, the US Food Drug Administration (USFDA) in the year 2008, mandated that all new antidiabetic agents must undergo an adequately powered, glycemic‐equipoised, cardiovascular (CV) outcome trial (CVOT) in high‐risk Type 2 diabetic patients, during postmarketing phase to demonstrate its safety by showing noninferiority against placebo. While noninferiority was de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Asian Journal of Medical Sciences
سال: 2021
ISSN: 2091-0576,2467-9100
DOI: 10.3126/ajms.v12i3.32477